English | 简体中文 | 繁體中文 | 한국어 | 日本語
 Press Releases for Wednesday, June 5, 2024
GMG's THERMAL-XR(R) Energy Savings Coating Wins Industry Product Excellence Award 
20:09 HKT/SGT
MHI and EGAT sign MoU to Introduce Hydrogen Large Gas Turbine Co-firing Technology in Thailand to Achieve Net Zero Goals 
18:09 HKT/SGT
Mitsubishi Shipbuilding Receives Additional Order for 2 Units of LNG Fuel Gas Supply System (FGSS) 
17:14 HKT/SGT
NEC announces external appointment of executive personnel 
16:43 HKT/SGT
3rd Clean Power & New Energy 2024; Take a Deep Dive into the Latest Transition of Renewable Energies 
15:31 HKT/SGT
Startup ecosystem in Southeast Asia and India show signs of maturity - Profitability and customer-centricity take centre stage: HubSpot Study 
15:00 HKT/SGT
Pride for All: Thailand Celebrates and Empowers Equality and Gender Diversity for Pride Month 2024 
14:00 HKT/SGT
Advancing Customer Experience Solutions at World CX Summit and Awards 
13:40 HKT/SGT
Kucingko Inks Underwriting Agreement with Kenanga Investment Bank 
13:00 HKT/SGT
Fintech360 and TradingView Enter into Partnership for Innovation and Efficiency 
12:00 HKT/SGT
三菱造船、LNG燃料ガス供給システム(FGSS)2基を追加受注 
11:47 HKT/SGT
JCB collaborates with Singapore's Mandai Wildlife Group to promote wildlife park visitorship 
11:00 HKT/SGT
君聖泰醫藥將在2024年國際肝病大會發布MASH臨床2a期研究分析結果,進一步展現熊去氧膽小檁鹼(HTD1801)的療效與安全性 
09:00 HKT/SGT
君圣泰医药将在2024年国际肝病大会发布MASH临床2a期研究分析结果,进一步展现熊去氧胆小檗碱(HTD1801)的疗效与安全性 
09:00 HKT/SGT
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801) 
09:00 HKT/SGT
Rover Announces Intent to Pursue Strategic Alternatives for Its Cabin Gold Project 
07:00 HKT/SGT
 ACN Search:
 
TrustCSI 3.0 Navigates the 'Belt and Road' and Empowers Global Enterprise's Digital Journey
 
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575